Stock Scorecard
Stock Summary for BioNTech SE (BNTX) - $105.27 as of 5/27/2023 12:07:21 AM
Total Score
18 out of 29
Currently on the following lists
Dividend Stock List
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for BNTX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BNTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BNTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for BNTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for BNTX
Financial Details for BNTX
Company Overview |
|
|---|---|
| Company Name | BioNTech SE |
| Country | USA |
| Description | BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 3/31/2023 |
| Next Earnings Date | 8/7/2023 |
Stock Price History |
|
| Last Day Price | 105.27 |
| Last Day Volume | 871,090 |
| Average Daily Volume | 815,027 |
| 52-Week High | 188.99 |
| 52-Week Low | 100.08 |
| Last Price to 52 Week Low | 5.19 % |
Valuation Measures |
|
| Trailing PE | 4.11 |
| Industry PE | 213.94 |
| Sector PE | 75.80 |
| 5-Year Average PE | 27.25 |
| Free Cash Flow Ratio | 2.09 |
| Industry Free Cash Flow Ratio | 35.79 |
| Sector Free Cash Flow Ratio | 37.36 |
| Current Ratio Most Recent Quarter | 12.95 |
| Total Cash Per Share | 50.39 |
| Book Value Per Share Most Recent Quarter | 84.09 |
| Price to Book Ratio | 2.33 |
| Industry Price to Book Ratio | 11.07 |
| Sector Price to Book Ratio | 15.29 |
| Price to Sales Ratio Twelve Trailing Months | 2.38 |
| Industry Price to Sales Ratio Twelve Trailing Months | 42.22 |
| Sector Price to Sales Ratio Twelve Trailing Months | 24.84 |
Share Statistics |
|
| Total Shares Outstanding | 240,990,000 |
| Market Capitalization | 25,369,017,300 |
| Institutional Ownership | 0.00 % |
Dividends |
|
| Ex-Dividend Date | 6/2/2022 |
| Last Dividend Amount | 3.65 |
| Current Dividend Amount | 2.11 |
| Dividend Aristocrat? | False |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00 % |
| Trailing Annual Dividend Rate | 3.65 |
| Trailing Annual Dividend Yield | 1.33 % |
| 5-Year Average Dividend Yield | 0.00 % |
| 5-Year Dividend Payments Count | 1 |
| Dividend Payout Ratio | 0.00 % |
Income Statement |
|
| Quarterly Earnings Growth YOY | -85.60 % |
| Annual Earnings Growth | -8.34 % |
| Reported EPS Past Year | 2.05 |
| Reported EPS Prior Year | 36.93 |
| Net Income Twelve Trailing Months | 6,237,800,000 |
| Net Income Past Year | 9,434,400,000 |
| Net Income Prior Year | 10,292,500,000 |
| Quarterly Revenue Growth YOY | -80.00 % |
| 5-Year Revenue Growth | 241.30 % |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 12,143,900,000 |
| Total Cash Past Year | 13,875,100,000 |
| Total Cash Prior Year | 1,692,700,000 |
| Net Cash Position Most Recent Quarter | 11,971,500,000 |
| Net Cash Position Past Year | 13,698,900,000 |
| Long Term Debt Past Year | 176,200,000 |
| Long Term Debt Prior Year | 171,600,000 |
| Total Debt Most Recent Quarter | 172,400,000 |
| Equity to Debt Ratio Past Year | 0.99 |
| Equity to Debt Ratio Most Recent Quarter | 0.99 |
| Total Stockholder Equity Past Year | 20,055,600,000 |
| Total Stockholder Equity Prior Year | 11,893,700,000 |
| Total Stockholder Equity Most Recent Quarter | 20,265,300,000 |
Options |
|
| Put/Call Ratio | 1.07 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| MACD | -2.26 |
| MACD Signal | -3.82 |
| 20-Day Bollinger Lower Band | 139.84 |
| 20-Day Bollinger Middle Band | 161.18 |
| 20-Day Bollinger Upper Band | 182.52 |
| Beta | 0.21 |
| RSI | 50.68 |
| 50-Day SMA | 142.40 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 5/27/2023 12:07:21 AM |